Group Roger Olofsson Bagge

Research summary

Our group focus on translational research, bringing new treatments to patients through novel clinical trials. The focus is primarily on breast cancer and malignant melanoma, and we work broadly from clinical trials, aspects on quality of life, immunology and extra-cellular vesicles.
 

Current group members

Roger Olofsson Bagge, Professor, Senior consultant surgeon and Group leader at Sahlgrenska Center for Cancer Research and The Wallenberg Center for Molecular and Translational Medicine
Karin Ekström, Associate professor, Senior researcher
Rossella Crescitelli, Senior researcher
Ann-Sophie Lindqvist Bagge, Associate professor, Senior researcher
Anders Carlander, Senior Researcher
Somsundar Veppil Muralidharan, Senior Researcher
Anne Huibers, PhD Postdoc
Emma Symonds, PhD, Postdoc
Elodie Barthout, PhD, Postdoc
Lijuan Yu, PhD, Postdoc
Måns Kadefors, PhD, Postdoc
Nazia Riaz, PhD, Postdoc
Andrew Wong, PhD student
Ellen Krabbe, PhD student
Lida Pistioli, PhD student
Therese Bengtsson, Research nurse
Désirée Bourghardt Wiklund, Research nurse
Sarah Palm, Research nurse
Elin Skalin, Research administrator

Selected recent publications

1. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). 
   Olofsson Bagge R, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, Helgadottir H, Kiilgaard JF, Kinhult S, Ljuslinder I, Mattsson J, Rizell M, Sternby Eilard M, Ullenhag GJ, Nilsson JA, Ny L, Lindnér P.
   J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705. Online ahead of print. PMID: 36940407
    
2. Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. 
   Crescitelli R, Filges S, Karimi N, Urzì O, Alonso-Agudo T, Ståhlberg A, Lötvall J, Lässer C, Olofsson Bagge R.
   Front Cell Dev Biol. 2022 Dec 1;10:1028854. doi: 10.3389/fcell.2022.1028854. eCollection 2022. PMID: 36531960 Free PMC article.
    
3. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse. 
   Mulder EEAP, Johansson I, Grünhagen DJ, Tempel D, Rentroia-Pacheco B, Dwarkasing JT, Verver D, Mooyaart AL, van der Veldt AAM, Wakkee M, Nijsten TEC, Verhoef C, Mattsson J, Ny L, Hollestein LM, Olofsson Bagge R.
   Cancers (Basel). 2022 Jun 9;14(12):2854. doi: 10.3390/cancers14122854. PMID: 35740520 Free PMC article.
    
4. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. 
   Holmberg CJ, Ny L, Hieken TJ, Block MS, Carr MJ, Sondak VK, Örtenwall C, Katsarelias D, Dimitriou F, Menzies AM, Saw RP, Rogiers A, Straker RJ 3rd, Karakousis G, Applewaite R, Pallan L, Han D, Vetto JT, Gyorki DE, Tie EN, Vitale MG, Ascierto PA, Dummer R, Cohen J, Hui JY, Schachter J, Asher N, Helgadottir H, Chai H, Kroon H, Coventry B, Rothermel LD, Sun J, Carlino MS, Duncan Z, Broman K, Weber J, Lee AY, Berman RS, Teras J, Ollila DW, Long GV, Zager JS, van Akkooi A, Olofsson Bagge R.
   Eur J Cancer. 2022 Jul;169:210-222. doi: 10.1016/j.ejca.2022.03.041. Epub 2022 May 26. PMID: 35644725
    
5. Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer. 
   Ekström K, Crescitelli R, Pétursson HI, Johansson J, Lässer C, Olofsson Bagge R.
   BMC Cancer. 2022 Jan 10;22(1):50. doi: 10.1186/s12885-021-08870-w. PMID: 35012489 Free PMC article.
    
6. Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity - The MAGMEN feasibility study. 
   Mirzaei N, Katsarelias D, Zaar P, Jalnefjord O, Johansson I, Leonhardt H, Wärnberg F, Olofsson Bagge R.
   Eur J Surg Oncol. 2022 Feb;48(2):326-332. doi: 10.1016/j.ejso.2021.12.467. Epub 2022 Jan 1. PMID: 35000820
    
7. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. 
   Johansson I, Tempel D, Dwarkasing JT, Rentroia-Pacheco B, Mattsson J, Ny L, Olofsson Bagge R.
   Eur J Surg Oncol. 2022 Feb;48(2):320-325. doi: 10.1016/j.ejso.2021.11.010. Epub 2021 Nov 10. PMID: 34794843
    
8. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. 
   Bethlehem MS, Katsarelias D, Olofsson Bagge R.
   Cancers (Basel). 2021 Sep 21;13(18):4726. doi: 10.3390/cancers13184726. PMID: 34572953 Free PMC article. Review.
    
9. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. 
   Olofsson Bagge R, Ny L, Ascierto PA, Hodi FS, Larkin J, Robert C, Schachter J, Weber JS, Long GV, van Akkooi ACJ.
   Melanoma Res. 2021 Apr 1;31(2):181-185. doi: 10.1097/CMR.0000000000000719. PMID: 33625104 Clinical Trial.
    
10. Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis. 
    Janeva S, Zhang C, Kovács A, Parris TZ, Crozier JA, Pezzi CM, Linderholm B, Audisio RA, Olofsson Bagge R.
    Lancet Healthy Longev. 2020 Dec;1(3):e117-e124. doi: 10.1016/S2666-7568(20)30018-0. Epub 2020 Nov 30. PMID: 36094184
     
11. Molecular profiling of driver events in metastatic uveal melanoma. 
    Karlsson J, Nilsson LM, Mitra S, Alsén S, Shelke GV, Sah VR, Forsberg EMV, Stierner U, All-Eriksson C, Einarsdottir B, Jespersen H, Ny L, Lindnér P, Larsson E, Olofsson Bagge R, Nilsson JA.
    Nat Commun. 2020 Apr 20;11(1):1894. doi: 10.1038/s41467-020-15606-0.
    PMID: 32313009 Free PMC article.

More group Roger Olofsson Bagge publications on PubMed